Trial · NCT02585778
Results by group156
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 156
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T1DM Participants | -51.8 | Standard Error 3.7 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | Placebo Q2W: T1DM Participants | -3.9 | Standard Error 5.3 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T2DM Participants | -48.2 | Standard Error 1.6 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | Placebo Q2W: T2DM Participants | 0.8 | Standard Error 2.2 | percent change | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Any AE | 64.5 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Placebo Q2W | Any AE | 64.1 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Any Serious AE | 9.0 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Placebo Q2W | Any Serious AE | 9.4 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Any AE leading to death | 0 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Placebo Q2W | Any AE leading to death | 0.6 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Any AE leading to treatment discontinuation | 4.9 | percentage of participants | |
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | Placebo Q2W | Any AE leading to treatment discontinuation | 2.4 | percentage of participants | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T1DM Participants | -53.8 | Standard Error 3.7 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Placebo Q2W: T1DM Participants | -3.2 | Standard Error 5.3 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T2DM Participants | -50.9 | Standard Error 1.6 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Placebo Q2W: T2DM Participants | 0.7 | Standard Error 2.2 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T1DM Participants | -49.4 | Standard Error 3.7 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Placebo Q2W: T1DM Participants | -1.1 | Standard Error 5.4 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T2DM Participants | -43.3 | Standard Error 1.6 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Placebo Q2W: T2DM Participants | 2.4 | Standard Error 2.2 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02585778/results